Levetiracetam monotherapy in Alzheimer patients with late‐onset seizures: a prospective observational study
- 26 July 2007
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 14 (10) , 1176-1178
- https://doi.org/10.1111/j.1468-1331.2007.01907.x
Abstract
Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new‐onset epileptic seizures in a prospective open‐label study. At a daily dose of 1000–1500 mg, 72% were seizure‐free for at least one year; 16% discontinued for untolerability; 8% were unresponsive; 4% were lost to follow‐up. These results suggest the need for controlled studies to confirm if LEV can be a first‐choice drug in AD.Keywords
This publication has 11 references indexed in Scilit:
- Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsyNeurology, 2007
- Epilepsy in the ElderlyEpilepsia, 2006
- Incidence and Predictors of Seizures in Patients with Alzheimer's DiseaseEpilepsia, 2006
- Effects of Levetiracetam on Nocturnal Sleep and Daytime Vigilance in Healthy VolunteersEpilepsia, 2006
- Clinical Pharmacokinetics of New-Generation Antiepileptic Drugs at the Extremes of AgeClinical Pharmacokinetics, 2006
- Cognitive and memory effects of the new antiepileptic drugsEpilepsy Research, 2005
- Special considerations in treating the elderly patient with epilepsyNeurology, 2004
- Limitations of monotherapy trials in epilepsyNeurology, 2003
- Effect of Antiepileptic Drugs on Cognitive Function in Individuals with EpilepsyDrugs, 2002
- Advanced Alzheimer's Disease Is a Risk Factor for Late-Onset SeizuresArchives of Neurology, 1990